Filtered By:
Source: Circulation
Procedure: Angioplasty
This page shows you your search results in order of date.
Order by Relevance | Date
Total 39 results found since Jan 2013.
Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial
CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT02100722.PMID:37602376 | DOI:10.1161/CIRCULATIONAHA.123.065770
Source: Circulation - August 21, 2023 Category: Cardiology Authors: Frederik M Zimmermann Victoria Y Ding Nico H J Pijls Zsolt Piroth Albert H M van Straten Laszlo Szekely Giedrius Davidavicius Gintaras Kalinauskas Samer Mansour Rajesh Kharbanda Nikolaos Östlund-Papadogeorgos Adel Aminian Keith G Oldroyd Nawwar Al-Attar Source Type: research
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction in STREAM-2: A Randomized, Open-Label Trial
CONCLUSIONS: Halving the dose of tenecteplase in a pharmaco-invasive strategy in this early-presenting, older STEMI population was associated with electrocardiographic changes that were at least comparable to those after primary PCI. Similar clinical efficacy and angiographic end points occurred in both treatment groups. The risk of intracranial hemorrhage was higher with half-dose tenecteplase than with primary PCI. If timely PCI is unavailable, this pharmaco-invasive strategy is a reasonable alternative, provided that contraindications to fibrinolysis are observed and excess anticoagulation is avoided.REGISTRATION: URL: ...
Source: Circulation - July 13, 2023 Category: Cardiology Authors: Frans Van de Werf Arsen D Risti ć Oleg V Averkov Alexandra AriasMendoza Yves Lambert Jos é F Kerr Saraiva Pablo Sepulveda Fernando Rosell-Ortiz John K French Ljilja B Musi ć Katleen Vandenberghe Kris Bogaerts Cynthia M Westerhout Alain Pag ès Thierry Source Type: research
Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: the HOST-EXAM Extended Study
Conclusions: During an extended follow-up of over 5 years after randomization, clopidogrel monotherapy as compared with aspirin monotherapy was associated with lower rates of the composite net clinical outcome in patients without clinical events for 12±6 months after PCI with DES.PMID:36342475 | DOI:10.1161/CIRCULATIONAHA.122.062770
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Jeehoon Kang Kyung Woo Park Huijin Lee Doyeon Hwang Han-Mo Yang Seung-Woon Rha Jang-Whan Bae Nam Ho Lee Seung Ho Hur Jung-Kyu Han Eun-Seok Shin Bon-Kwon Koo Hyo-Soo Kim Source Type: research
Indobufen or Aspirin on Top of Clopidogrel after Coronary Drug-eluting Stent Implantation (OPTION): a Randomized, Open-label, Endpoint-blinded, Non-inferiority Trial
Conclusions: In Chinese patients with negative cardiac troponin undergoing DES implantation, indobufen plus clopidogrel DAPT compared with aspirin plus clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, which was mainly driven by a reduction in bleeding events without an increase in ischemic events.PMID:36335890 | DOI:10.1161/CIRCULATIONAHA.122.062762
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Hongyi Wu Lili Xu Xin Zhao Huanyi Zhang Kang Cheng Xiaoyan Wang Manhua Chen Guangping Li Jiangnan Huang Jun Lan Guanghe Wei Chi Zhang Yinman Wang Juying Qian Junbo Ge Source Type: research
Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-up Outcomes of Multicenter Randomized Controlled BEST Trial
CONCLUSIONS: In patients with multivessel coronary artery disease, there were no significant differences between PCI and CABG in the incidence of major adverse cardiac events, safety composite end point, and all-cause mortality during extended-follow-up.PMID:36121700 | DOI:10.1161/CIRCULATIONAHA.122.062188
Source: Circulation - September 19, 2022 Category: Cardiology Authors: Jung-Min Ahn Do-Yoon Kang Sung-Cheol Yun Seung Ho Hur Hun-Jun Park Damras Tresukosol Woon Chol Kang Hyuck Moon Kwon Seung-Woon Rha Do-Sun Lim Myung-Ho Jeong Bong-Ki Lee He Huang Young Hyo Lim Jang Ho Bae Byung-Ok Kim Tiong Kiam Ong Sung Gyun Ahn Cheol-Hyu Source Type: research
